Robert Naismith on Muck Rack

Robert Naismith

Missouri
As seen in: Wiley Online Library, Memory Studies, SAGE Publishing, The Lancet, Neurology, Scranton Times-Tribune, Future Medicine, NEJM Journal Watch, NeurologyLive, Multiple Sclerosis and Related Disorders
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Robert

Contact Robert, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial

|
By Peter A Calabresi, Gavin Giovannoni, Hans-Peter Hartung, Robert Naismith
| SAGE Publishing
Abstract Background: Opicinumab, a human monoclonal antibody against LINGO-1, is hypothesized to promote remyelination by enhancing the differentiation of oligodendrocyte progenitor cells. Objective: The objective of the study is to investigate the efficacy and safety of opicinumab as an add-on therapy to anti-inflammatory disease-modifying therapies (DMTs) in participants with relapsing multiple sclerosis (RMS).
Open in Who Shared Issue with article?

Do Disease-Modifying Therapies Benefit Patients with Late-Onset Multiple Sclerosis?

|
By Robert Naismith
| NEJM Journal Watch
Robert T. Naismith, MD, reviewing A registry study associated these therapies with lower relapse rates and MRI activity but not with an impact on disability progression. Patients with late-onset multiple sclerosis (LOMS), defined as disease onset at age 55 or later, face unique therapeutic challenges because LOMS is linked to lower inflammatory activity and more comorbidities than adult-onset MS ( NEJM JW Neurol Mar 26 2024 and Neurology 2024; 102:e208051).
Open in Who Shared Issue with article?

How Should We Manage Multiple Sclerosis Therapies During Pregnancy?

|
By Robert Naismith
| NEJM Journal Watch
Open in Who Shared Issue with article?
See all 240 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Robert

Contact Robert, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified